Anti-Xa levels after a subcutaneous injection of 5700 IU nadroparin in morbidly obese patients

被引：0
|
作者：
Diepstraten, J. [1 ]
Janssen, E. J. H. [1 ]
Hackeng, C. M. [2 ]
van Kralingen, S. [3 ]
van Dongen, E. P. A. [3 ]
Wiezer, M. J. [4 ]
van Ramshorst, B. [4 ]
Knibbe, C. A. J. [1 ,5 ]
机构：
[1] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands
[2] St Antonius Hosp, Dept Clin Chem, Nieuwegein, Netherlands
[3] St Antonius Hosp, Dept Anaesthesiol & Intens Care, Nieuwegein, Netherlands
[4] St Antonius Hosp, Dept Surg, Nieuwegein, Netherlands
[5] Leiden Univ, Div Pharmacol, Ctr Drug Res, Leiden, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 73卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [1] Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients
    Jeroen Diepstraten
    Christian M. Hackeng
    Simone van Kralingen
    Jiri Zapletal
    Eric P. A. van Dongen
    René J. Wiezer
    Bert van Ramshorst
    Catherijne A. J. Knibbe
    [J]. Obesity Surgery, 2012, 22 : 791 - 796
  • [2] Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients
    Diepstraten, Jeroen
    Hackeng, Christian M.
    van Kralingen, Simone
    Zapletal, Jiri
    van Dongen, Eric P. A.
    Wiezer, Rene J.
    van Ramshorst, Bert
    Knibbe, Catherijne A. J.
    [J]. OBESITY SURGERY, 2012, 22 (05) : 791 - 796
  • [3] POPULATION PHARMACODYNAMICS OF NADROPARIN IN MORBIDLY OBESE PATIENTS USING ANTI-XA LEVELS AS PHARMACODYNAMIC ENDPOINT
    Diepstraten, J.
    Janssen, E. J.
    Hacking, C. M.
    van Kralingen, S.
    Peeters, M. Y.
    van Dongen, E. P.
    Wiezer, R. J.
    van Ramshorst, B.
    Knibbe, C. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S27 - S27
  • [4] Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis
    Heizmann, M
    Baerlocher, GM
    Steinmann, F
    Horber, FF
    Wuillemin, WA
    [J]. THROMBOSIS RESEARCH, 2002, 106 (4-5) : 179 - 181
  • [5] Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery
    Thom Kok
    Hans de Boer
    Bart Witteman
    Marcel Hovens
    Matthijs van Luin
    Houshang Monajemi
    [J]. Obesity Surgery, 2022, 32 : 607 - 614
  • [6] Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery
    Kok, Thom
    de Boer, Hans
    Witteman, Bart
    Hovens, Marcel
    van Luin, Matthijs
    Monajemi, Houshang
    [J]. OBESITY SURGERY, 2022, 32 (03) : 607 - 614
  • [7] Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint
    Diepstraten, Jeroen
    Janssen, Esther J. H.
    Hackeng, Christian M.
    van Dongen, Eric P. A.
    Wiezer, Rene J.
    van Ramshorst, Bert
    Knibbe, Catherijne A. J.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (01) : 25 - 34
  • [8] Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint
    Jeroen Diepstraten
    Esther J. H. Janssen
    Christian M. Hackeng
    Eric P. A. van Dongen
    René J. Wiezer
    Bert van Ramshorst
    Catherijne A. J. Knibbe
    [J]. European Journal of Clinical Pharmacology, 2015, 71 : 25 - 34
  • [9] NADROPARIN AND ANTI-XA ACTIVITY AFTER BARIATRIC SURGERY
    Schijns, W.
    Aarts, E.
    Homan, J.
    Dogan, K.
    Betzel, B.
    Kaasjager, K.
    Janssen, I.
    Berends, F.
    [J]. OBESITY SURGERY, 2014, 24 (08) : 1259 - 1260
  • [10] NADROPARIN AND ANTI-XA ACTIVITY AFTER BARIATRIC SURGERY
    Schijns, Wendy
    Homan, Jens
    Aarts, Edo
    Dogan, Kemal
    Betzel, Bark
    Janssen, Ignace
    Deenen, Maarten
    Kaasjager, Karin
    Berends, F. J.
    [J]. OBESITY SURGERY, 2015, 25 : S52 - S52
12345